Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2026-02-06 00:00:00 ET · period of report 2026-02-04 · accession 0001995218-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-06 | 2026-02-04 | LXEO | Townsend Richard Nolan | CEO, Dir | A - Grant | $0.00 | +161.7K | 402.7K | +67% | $0 |
| D | 2026-02-06 | 2026-02-04 | LXEO | Townsend Richard Nolan | CEO, Dir | A - Grant | $0.00 | +646.7K | 646.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-04 | A | A | 161,665 | $0.00 | 402,656 | D | — | — | (F1) The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date. (F2) Includes 290,022 RSUs. |
| 2 | Derivative | Stock Option (right to buy) | 2026-02-04 | A | A | 646,665 | $0.00 | 646,665 | D | $7.27 · — to 2036-02-03 | 260,000 Common Stock | (F3) 25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |